BioMarin Pharmaceutical finds itself in an uncomfortable position this week: short sellers have been adding steadily even as a broad analyst consensus insists the stock is worth far more than its current price. The short interest story is the week's clearest tension. Bears have been building positions for over a month. At 6.6% of free float, short interest has risen 27.7% over the…
BMRN cost to borrow surges 178% in one week to 0.33%, lowest level on record but sharply reversing from recent lows.
Key data as of 4 Nov 2026
BMRN heads into its October 27 earnings report with a striking disconnect: short sellers are rebuilding positions at the fastest rate in months, yet options traders are growing more bullish than at almost any point in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BMRN — free to start on ORTEX.
Sign up for free →Open BMRN on ORTEX